UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000024497
Receipt number R000028194
Scientific Title Phase I clinical trial of WT1 vaccination for MDS with dose escalation
Date of disclosure of the study information 2016/10/20
Last modified on 2018/04/23 12:43:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase I clinical trial of WT1 vaccination for MDS with dose escalation

Acronym

Phase I clinical trial of WT1 vaccination for MDS

Scientific Title

Phase I clinical trial of WT1 vaccination for MDS with dose escalation

Scientific Title:Acronym

Phase I clinical trial of WT1 vaccination for MDS

Region

Japan


Condition

Condition

MDS

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of safety of WT1 vaccination in MDS patients

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Frequencies of adverse events (Grade3,4)

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Intradermal injection of WT1 peptides biweekly

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients diagnosed as MDS
HLA-A2402
Elevated WT1 expression in peripheral blood or bone marrow

Key exclusion criteria

Dysfunction of major organs

Target sample size

3


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Haruo Sugiyama

Organization

Osaka University

Division name

Cancer Immunoligy

Zip code


Address

1-7, yamada-Oka, Suita

TEL

0668792597

Email

sugiyama@sahs.med.osaka-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Naoki Hosen

Organization

Osaka University Graduate School of Medicine

Division name

Cancer Stem Cell Biology

Zip code


Address

1-7, Yamada-Oka

TEL

0668793676

Homepage URL


Email

hnaoki@imed3.med.osaka-u.ac.jp


Sponsor or person

Institute

Osaka University Dept of Cancer Immunology

Institute

Department

Personal name



Funding Source

Organization

Dept of Cancer Immunotherapy, Osaka Univ.

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 10 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 10 Month 11 Day

Date of IRB


Anticipated trial start date

2016 Year 10 Month 11 Day

Last follow-up date

2018 Year 03 Month 31 Day

Date of closure to data entry

2018 Year 03 Month 31 Day

Date trial data considered complete

2018 Year 03 Month 31 Day

Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 10 Month 20 Day

Last modified on

2018 Year 04 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028194


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name